

Let Your Patients Know.

NEPHROTIC SYNDROME CLINICAL TRIALS ARE HAPPENING.

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
DUPLEX (Retrophin)	FSGS	12-75	Sparsentan	≥30
THE PODO TRIAL (Pfizer)	FSGS	18-70	PF- 06730512	≥45
PODOCYTE STUDY (Mallinckrodt)	FSGS	18+	Acthar	≥30
AURONA (Aurinia)	FSGS	18-75	Voclosporin	>30
LUMINA STUDIES (ChemoCentryx)	FSGS	18+	CCX140-B	>30
FIRSTx (Complexa)	FSGS	18+	CXA-10	≤40
LIPOSORBER LA-15 SYSTEM FOR CHILDREN WITH FSGS (Kaneka)	Post transplant FSGS Recurrence	5-21	Liposorber LA-15 System	≥60 or post-trans- plant recurrence
PHOENIX TRIAL (ENROLLMENT COMPLETE) (Reata)	FSGS or IgAN	18-65	Bardoxolone methyl	≥30
EFFICACY & SAFETY OF BLESELUMAB TO PREVENT RECURRENCE (Astellas)	De novo transplant due to FSGS	18+	Bleselumab (added to SOC)	N/A
PROTECT (Retrophin)	IgAN	18+	Sparsentan	≥30
EFFICACY AND SAFETY IN IGA WITH RISK OF ESRD (NEFIGARD) (Calliditas)	IgAN	18+	Nefecon	≥45
EFFICACY AND SAFETY OF OMS721 IN IGAN PATIENTS (Omeros)	IgAN	18+	OMS721	≥30
ATACICEPT IN IGA NEPHROPATHY (EMD Serono)	IgAN	18+	Atacicept	N/A
THE DISCOVERY TRIAL (Apellis)	IgAN, C3G MN, Lupus Nephritis Dense Deposit Disease	18+	APL-2	≥30
ACH-0144471 FOR C3G (Achillion)	C3G, Dense Deposit Disease	17-65	Ach-0144471	>30

Visit KidneyHealthGateway.com to stay current on trials for your Nephrotic Syndrome patients.



NEPHCURE[®]
Kidney International